Dihydrotestosterone (DHT)

For research use only.

Catalog No.S4757 Synonyms: androstanolone, stanolone, 5α-DHT

6 publications

Dihydrotestosterone (DHT) Chemical Structure

CAS No. 521-18-6

Dihydrotestosterone (DHT, androstanolone, stanolone, 5α-DHT) is an endogenous androgen sex steroid and hormone and a potent agonist of the androgen receptor with 2-3-fold greater androgen receptor affinity than testosterone and 10-fold higher potency of inducing androgen receptor signaling.

Size Price Stock Quantity  
10mM (1mL in DMSO) USD 167 In stock
USD 157 In stock
USD 370 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Selleck's Dihydrotestosterone (DHT) has been cited by 6 publications

Purity & Quality Control

Choose Selective Androgen Receptor Inhibitors

Biological Activity

Description Dihydrotestosterone (DHT, androstanolone, stanolone, 5α-DHT) is an endogenous androgen sex steroid and hormone and a potent agonist of the androgen receptor with 2-3-fold greater androgen receptor affinity than testosterone and 10-fold higher potency of inducing androgen receptor signaling.
Targets
Androgen Receptor [1]
()
In vitro

In AR-positive bladder cancer UMUC3 and TCC-SUP cells, dihydrotestosterone (DHT) increased the expression of EGFR and ERBB2 both in mRNA and in protein levels. DHT additionally upregulated the levels of phosphorylation of EGFR (pEGFR) and its downstream proteins AKT (pAKT) and ERK1/2 (pERK), induced by EGF treatment, in AR-positive cells[1].

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
CV-1 cell M2nBUGZ2dmO2aX;uJIF{e2G7 NETEWJBC\2:waYP0bYMh[WO2aY\peJkhMEWFNUCpJIFo[Wmwc4SgbJVu[W5iYX7kdo9o\W5icnXj[ZB1d3JiZYjwdoV{e2WmIHnuJGNXNTFiY3XscEwhTUN3ME2wMlAxPiEQvF2= MW[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek86QDdzNUO0K|46QDdzNUO0QE9iRg>?
MDA-MB-453 cell NHPyWZhHfW6ldHnvckBie3OjeR?= M2LCPGRqe3CuYXPlcYVvfCCxZjDbN2heTEiWIH\yc40hcHWvYX6gZY5lem:pZX6gdoVk\XC2b4Kg[ZhxemW|c3XkJIlvKE2GQT3NRk01PTNiY3XscJMh[nlid3jvcIUh[2WubDDy[YNmeHSxcjDibY5lcW6pIHHzd4F6NCCNaU2wMlAxODJizszN MkHVQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTdyM{SxNVcoRjF5MEO0NVE4RC:jPh?=
HepG2 cell MoDnSpVv[3Srb36gZZN{[Xl? M3rSNWFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iYX7kdo9o\W5icnXj[ZB1d3JiZYjwdoV{e2WmIHnuJGhmeEd{IHPlcIx{KGG|c3Xzd4VlKGG|IHz1Z4ln\XKjc3WgdoVxd3K2ZYKg[4Vv\SCjY4TpeoF1cW:wLDDJR|UxRTBwMEG4NkDPxE1? M{DwSlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF5MUS5PFY3Lz5zN{G0PVg3PjxxYU6=
MDA453 cell M{fjPWZ2dmO2aX;uJIF{e2G7 NVrpU3NmTGm|cHzhZ4Vu\W62IH;mJHs{UF2GSGSg[pJwdSCqdX3hckBCWiCrbjDNSGE1PTNiY3XscJMtKEurPUCuNFA{KM7:TR?= NIfZdYg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zN{G4NVE1OSd-MUexPFEyPDF:L3G+
mouse C2C12 cell NYfI[417TnWwY4Tpc44h[XO|YYm= NVu4d5JvSWexbnnzeEBi[3Srdnn0fUBifCC{YYSgRXIhfHKjboPm[YN1\WRiaX6gcY92e2ViQ{LDNVIh[2WubIOgZpkhdHWlaX\ldoF{\SC{ZYDvdpRmeiC2cnHud4FkfGm4YYTpc44h[XO|YYmsJGVEPTB;MD6wNlgh|ryP MUe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPzF6MUG0NUc,OTdzOEGxOFE9N2F-
monkey COS7 cell M1\HfmZ2dmO2aX;uJIF{e2G7 M{j0XWJqdmSrbnegZYZncW6rdImgeI8hcHWvYX6gZY5lem:pZX6gdoVk\XC2b4Kg[ZhxemW|c3XkJIlvKG2xbnvlfUBEV1N5IHPlcIx{KGK7IIfoc4xmKGOnbHygZolv\GmwZzDhd5NigSxiS3m9NE4xODB{IN88US=> NELBTYs9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOES0NlkyOid-MUi0OFI6OTJ:L3G+
CHO cell M4PESmZ2dmO2aX;uJIF{e2G7 NXzjdHRvSWexbnnzeEBi[3Srdnn0fUBifCCqdX3hckBVT1J3IHX4dJJme3OnZDDpckBEUE9iY3XscJMh[nlibIXjbYZmemG|ZTDhd5NigSxiRVO1NF01NjR7IN88US=> NInWepE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOEOwO|I6PCd-MUizNFczQTR:L3G+
COS7 cell MUXGeY5kfGmxbjDhd5NigQ>? Ml\1RYdwdmm|dDDhZ5Rqfmm2eTDheEBpfW2jbjDhcoRzd2enbjDy[YNmeHSxcjDXO|QySyCvdYThcpQh\XiycnXzd4VlKGmwIFPPV|ch[2WubIOgZZN{\XO|ZXSgZZMhdHWlaX\ldoF{\SCjY4Tpeol1gSCjZoTldkAzPCCqcoOgZpkhemWyb4L0[ZIh\2WwZTDhd5NigSxiRVO1NF0xNjBzMjFOwG0> NGH4[289[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkC5OFI4QSd-MkKwPVQzPzl:L3G+
COS7 cell M1qyW2Z2dmO2aX;uJIF{e2G7 NHjSVXFC\2:waYP0JIFkfGm4aYT5JIF1KGi3bXHuJIFv\HKxZ3XuJJJm[2WydH;yJHQ5PzeDIH31eIFvfCCneIDy[ZN{\WRiaX6gR29UPyClZXzsd{Bie3Onc4Pl[EBieyCudXPp[oVz[XOnIHHjeIl3cXS7IHHmeIVzKDJ2IHjyd{BjgSC{ZYDvdpRmeiCpZX7lJIF{e2G7LDDFR|UxRTBwMEG1JO69VQ>? MkP2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJyOUSyO|koRjJ{MEm0Nlc6RC:jPh?=
COS7 cell NGraXJJHfW6ldHnvckBie3OjeR?= NULjRXVvSWexbnnzeEBi[3Srdnn0fUBifCCqdX3hckBidmS{b3flckBz\WOncITvdkBmgHC{ZYPz[YQhcW5iQ1;TO{Bk\WyuczDhd5Nme3OnZDDhd{BtfWOrZnXyZZNmKGGldHn2bZR6KGGodHXyJFI1KGi{czDifUBz\XCxcoTldkBo\W6nIHHzd4F6NCCHQ{WwQVAvODB4MjFOwG0> MoXxQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJyOUSyO|koRjJ{MEm0Nlc6RC:jPh?=
LNCaP-hr cell MlrHSpVv[3Srb36gZZN{[Xl? NYLNWXF4OyCmYYnz Mn3tRYdwdmm|dDDhZ5Rqfmm2eTDheEBCdmS{b3flckBz\WOncITvdkBVQDd5QTDteZRidnRiaX6gbJVu[W5iTF7DZXAucHJiY3XscJMh[XO|ZYPz[YQh[XNicILvd5RifGVic4DlZ4lncWNiYX70bYdmdiC|ZXPy[ZRqd25ibXXhd5Vz\WRiYX\0[ZIhOyCmYYnzJIJ6KGWweont[U1qdW23bn;hd5NigSxiRVO1NF0xNjBzNTFOwG0> NEjwVZg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{G5PVQ4Pyd-MkOxPVk1Pzd:L3G+
LNCaP-hr cell MXfGeY5kfGmxbjDhd5NigQ>? M{fXO|Mh\GG7cx?= M2izdWFod26rc4SgZYN1cX[rdImgZZQhf2muZDD0fZBmKEGwZILv[4VvKHKnY3XweI9zKGmwIHj1cYFvKEyQQ3HQMYhzKGOnbHzzJIF{e2W|c3XkJIF{KHC{b4P0ZZRmKHOyZXPp[olkKGGwdHnn[Y4he2WlcnX0bY9vKG2nYYP1doVlKGGodHXyJFMh\GG7czDifUBmdnq7bXWtbY1ufW6xYYPzZZktKEWFNUC9NE4xODZ{IN88US=> M4Xae|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ|MUm5OFc4Lz5{M{G5PVQ4PzxxYU6=
HEK293 cell MVTGeY5kfGmxbjDhd5NigQ>? MXjB[49vcXO2IHHjeIl3cXS7IHH0JIh2dWGwIHHu[JJw\2WwIILlZ4VxfG:{IHX4dJJme3OnZDDpckBJTUt{OUOgZ4VtdHNiYomgcJVkcW[ncnHz[UBz\XCxcoTldkBo\W6nIHHzd4F6NCCHQ{WwQVAvOThibl2= M1nMUVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3M{C1Olg5Lz5{NUOwOVY5QDxxYU6=
COS M{HuU2Z2dmO2aX;uJIF{e2G7 MX;CbY5lcW6pIHHm[olvcXS7IHHnZYlve3RiQX7kdo9o\W5icnXj[ZB1d3JiZYjwdoV{e2WmIFPPV{Bk\WyuczygT4khRSByLkCwNkDPxE1w NX\aXml5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxOUi3NVU{PCd-OUi3NVU{PDxxYU6=
COS-1 Ml\LSpVv[3Srb36gZZN{[Xl? NWX6dmFLSmmwZHnu[{Bi\m[rbnn0fUBnd3JiaIXtZY4hSW6mcn;n[Y4hemWlZYD0c5Ih\XiycnXzd4VlKGmwIFPPV{0yKGOnbHzzMEBMcSB;IECuNFA{KM7:TT6= MmjUQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwQTl{NUeyOUc,QTl{NUeyOVww[T5?
CV-1 MUnGeY5kfGmxbjDhd5NigQ>? MV\B[49vcXO2IHHjeIl3cXS7IHHnZYlve3RiSIXtZY4hSW6mcn;n[Y4hemWlZYD0c5Ih\XiycnXzd4VlKGmwIFPWMVEh[2WubIOsJGVEPTBiPTCwMlAxPSEQvF2u M2e3e|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493Nzl7MkW3NlUoRjl7MkW3NlU9N2F-
COS Ml;zSpVv[3Srb36gZZN{[Xl? M2fhRWlvKH[rdILvJIJqdmSrbnegZYZncW6rdImgZZQhcHWvYX6gZY5lem:pZX6gdoVk\XC2b4KgeJJidnOoZXP0[YQhcW62bzDDU3Mh[2WubIOuMEBKSzVyIE2gNE4xODRizszNMi=> Ml;oQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTB{M{C2NlgoRjFyMkOwOlI5RC:jPh?=
CV-1 MWrGeY5kfGmxbjDhd5NigQ>? NIrCWJlKdiC4aYTyc{Bi\2:waYP0bYMh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDhcoRzd2enbjDy[YNmeHSxcjD1d4lv\yClb4TyZY5{\mWldHnvckBie3OjeTDpckBEXi1zIHPlcIx{NixiRVO1NEA:KDBwMEC2JO69VS5? M3rzZ|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzFyMkOwOlI5Lz5zMEKzNFYzQDxxYU6=
CV-1 NUPEbZRiTnWwY4Tpc44h[XO|YYm= Mn;MRYdwdmm|dDDhZ5Rqfmm2eTD0c{B1cGViaIXtZY4h[W6mcn;n[Y4hemWlZYD0c5IhMGiDUjmgbY4hS1ZvMTDj[YxteyxiRVO1NEA:KDBwMEC2JO69VS5? M4DvVFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzFyM{SwOlI1Lz5zMEO0NFYzPDxxYU6=
CV1 M{nSbGZ2dmO2aX;uJIF{e2G7 MVvB[49vcXO2IHHjeIl3cXS7IHH0JIh2dWGwIHHu[JJw\2WwIILlZ4VxfG:{IHnuJGNXOSClZXzsd{Bu\WG|dYLl[EBieyC|dHnteYxifGmxbjDv[kBtfWOrZnXyZZNmKHKncH;yeIVzKGenbnWgZYN1cX[rdImgZpkh[2:2cnHud4Zm[3Srb36gZZN{[XluIFXDOVAhRSByLkCwOVEh|ryPLh?= MX28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPzB|NEGxO{c,OTdyM{SxNVc9N2F-
CV1 MV3GeY5kfGmxbjDhd5NigQ>? MmDXRolv\GmwZzDh[oZqdmm2eTD0c{BpfW2jbjDhcoRzd2enbjDy[YNmeHSxcjDlfJBz\XO|ZXSgbY4hS1ZzIHPlcIx{NCCNaTC9JFAvODByMjFOwG0v MlzUQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTd{NUe4N|goRjF5MkW3PFM5RC:jPh?=
CV1 NX3EOYxYTnWwY4Tpc44h[XO|YYm= MWTB[49vcXO2IHHjeIl3cXS7IHH0JIh2dWGwIHHu[JJw\2WwIILlZ4VxfG:{IHX4dJJme3OnZDDpckBEXjFiY3XscJMtKEWFNUCgQUAxNjByNUGg{txONg>? M4TyXFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF5MkW3PFM5Lz5zN{K1O|g{QDxxYU6=
MDA-MB-453 NVnQTWhkTnWwY4Tpc44h[XO|YYm= NETJbWVFcXOybHHj[Y1mdnRib3[gX|NJZUSKVDDmdo9uKGi3bXHuJGFTKGW6cILld5Nm\CCrbjDNSGEuVUJvNEWzJINmdGy|LDDLbUA:KDBwMECwN{DPxE1w NWrnOI5DRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUe0N|kyOTJpPkG3OFM6OTF{PD;hQi=>
CV1 NUjKNJpDTnWwY4Tpc44h[XO|YYm= M1O5bWFod26rc4SgZYN1cX[rdImgZZQhcHWvYX6gZY5lem:pZX6gdoVk\XC2b4Kg[ZhxemW|c3XkJIlvKEOYMTDj[YxteyCkeTD0doFve2O{aYD0bY9v[WxiYXP0bZZifGmxbjDhd5NigSxiRVO1NEA:KDBwMEC1O{DPxE1w NEDyfGs9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zN{SzPVEyOid-MUe0N|kyOTJ:L3G+
CV1 NEXNRm1HfW6ldHnvckBie3OjeR?= NVvGSWZ{SWexbnnzeEBi[3Srdnn0fUBifCCqdX3hckBidmS{b3flckBz\WOncITvdkBmgHC{ZYPz[YQhcW5iQ2[xJINmdGy|IHL5JJRz[W6|Y4LpdJRqd26jbDDhZ5RqfmG2aX;uJIF{e2G7LDDFR|UxKD1iMD6wNFU4KM7:TT6= NUS4eZNjRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUe3NFM6OzhpPkG3O|A{QTN6PD;hQi=>
MDA-MB-453 NFfTdHpHfW6ldHnvckBie3OjeR?= NUj0VIE6TGm|cHzhZ4Vu\W62IH;mJHs{UF2GSGSg[pJwdSCqdX3hckBCdmS{b3flckBz\WOncITvdkBqdiCqdX3hckBOTEFvTVKtOFU{KGOnbHzzMEBMcSB;IECuNFAxQSEQvF2u MVm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQDRyMES5PUc,OTh2MEC0PVk9N2F-
CV1 MmjBSpVv[3Srb36gZZN{[Xl? NXO3Zo5VSWexbnnzeEBi[3Srdnn0fUBifCCqdX3hckBidmS{b3flckBz\WOncITvdkBqdiCFVkGgZ4VtdHNiYomgeJJidnOlcnnweIlwdmGuIHHjeIl3[XSrb36gZZN{[XluIFXDOVAhRSByLkCwOVch|ryPLh?= M3zSU|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF6NECwOFk6Lz5zOESwNFQ6QTxxYU6=
Saos2 MUHGeY5kfGmxbjDhd5NigQ>? NU\aPHFMSWO2aY\peJkh[XRiYX7kdo9o\W5icnXj[ZB1d3JiaX6gbJVu[W5iU3Hvd|Ih[2WubIOgZZN{\XO|ZXSgZZMhUUx4IILldJJme3Orb36sJGlEPTBiPTCwMlAxODB3IN88UU4> MUO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQDR2MkmxNkc,OTh2NEK5NVI9N2F-
CV1 NULKVFd3TnWwY4Tpc44h[XO|YYm= M2jzVWFod26rc4SgZYN1cX[rdImgZZQhcHWvYX6gZY5lem:pZX6gdoVk\XC2b4KgZYZzcWOjbjDndoVmdiCvb37r[ZkhS1ZzIHPlcIx{KGK7IHPveJJidnOoZXP0bY9vKGG|c3H5MEBGSzVyIE2gNE4xODVzIN88UU4> NG\weFI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOES0NlkyOid-MUi0OFI6OTJ:L3G+
MDA-kb2 MWnGeY5kfGmxbjDhd5NigQ>? NH;RTYFC\2:waYP0JIFkfGm4aYT5JIF1KGGwZILv[4VvKHKnY3XweI9zKGmwIHj1cYFvKE2GQT3rZlIh[2WubIOgZZN{\XO|ZXSgZZMhe3SrbYXsZZRqd25ib3[gcJVkcW[ncnHz[UBi[3Srdnn0fUBjgSCudXPp[oVz[XOnIILldI9zfGW{IHflcoUh[XO|YYmsJGVEOTVyIE2gNE4xODB3IN88UU4> Ml;PQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTl3OUKyOFUoRjF7NUmyNlQ2RC:jPh?=
MDA-kb2 NWjpcG1jTnWwY4Tpc44h[XO|YYm= M3zNcGFod26rc4SgZYN1cX[rdImgZZQh\2y3Y3;jc5J1cWOxaXSgdoVk\XC2b4KgbY4hcHWvYX6gUWRCNWukMjDj[YxteyCjc4Pld5Nm\CCjczDzeIlufWyjdHnvckBw\iCudXPp[oVz[XOnIHHjeIl3cXS7IHL5JIx2[2moZYLhd4UhemWyb4L0[ZIh\2WwZTDhd5NigSxiRVOxOVAhRSByLkCwNFUh|ryPLh?= NUflbJF7RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUm1PVIzPDVpPkG5OVkzOjR3PD;hQi=>
MDA-MB-453 NVSzbIVqTnWwY4Tpc44h[XO|YYm= MoLYSIl{eGyjY3Xt[Y51KG:oIGuzTH1u\XSqeXz0dolmdm:ub37lJIZzd21iYX7kdo9o\W5icnXj[ZB1d3JiaX6gbJVu[W5iTVTBMW1DNTR3MzDj[YxteyxiSVO1NEA:KDBwMECxJO69VS5? M1nSWFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF7NkC2PFcxLz5zOU[wOlg4ODxxYU6=
MDA-MB-453 NVX0PVluTnWwY4Tpc44h[XO|YYm= NFju[FZC\2:waYP0JIFkfGm4aYT5JIF1KGGwZILv[4VvKHKnY3XweI9zKGmwIHj1cYFvKE2GQT3NRk01PTNiY3XscJMhfHKjboPm[YN1\WRid3n0bEBOVVSYLVzVR{Bie3Onc4Pl[EBieyCrbnT1Z5Rqd25ib3[gUW1VXi2OVGKvdJJwdW:2ZYKgcIlvc2WmIFzVR{Bo\W6nIHL5JIx2[2moZYLhd4UhfHKjboPhZ5RqfmG2aX;uJIF{e2G7LDDFR|UxKD1iMD6wNFIh|ryPLh?= MXK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQTZyNki3NEc,OTl4ME[4O|A9N2F-
NIH3T3 NGH4V4NHfW6ldHnvckBie3OjeR?= NFrVNVJC\2:waYP0JIFkfGm4aYT5JIF1KGGwZILv[4VvKHKnY3XweI9zKEyERDDUPFc4SSCvdYThcpQhcW5ibX;1d4UhVkmKM2SzJINmdGy|IITyZY5{cWWwdHz5JJRz[W6|ZnXjeIVlKHerdHigZoV1[S2pYXzhZ5Rwe2mmYYPlJJJmeG:{dHXyJIdmdmViYYPz[ZN{\WRiYYOgZ4VtdHWuYYKgeJJidnOob4LtZZRqd25iYomgVk1USVRiYYPzZZktKEWFNUCgQUAxNjByMUK1PUDPxE1w MmLvQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTl6NU[5NlEoRjF7OEW2PVIyRC:jPh?=
NIH3T3 NFvBO4JHfW6ldHnvckBie3OjeR?= NV\QOopKSWexbnnzeEBi[3Srdnn0fUBifCCjbnTyc4dmdiC{ZXPldJRweiCrbjDtc5V{\SCQSVizWFMh[2WubIOgeJJidnOrZX70cJkhfHKjboPm[YN1\WRid3n0bEBj\XSjLXfhcIFkfG:|aXThd4UhemWyb4L0[ZIh\2WwZTDhd5Nme3OnZDDhd{Bk\WyudXzhdkB1emGwc3\vdo1ifGmxbjDifUBTNVODVDDhd5NigSxiRVO1NEA:KDBwMECzPVgyKM7:TT6= MmXNQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTl6NU[5NlEoRjF7OEW2PVIyRC:jPh?=
COS7 M1z1TGZ2dmO2aX;uJIF{e2G7 M1jUNWFod26rc4SgZYN1cX[rdImgZZQh[W6mcn;n[Y4hemWlZYD0c5IhdGmpYX7kJIJqdmSrbneg[I9u[WmwIHX4dJJme3OnZDDpckBi\nKrY3HuJIdz\WWwIH3vcotmgSCFT2O3JINmdGy|IHPvMZRz[W6|ZnXjeIVlKHerdHigS4FtPC2GQlSgZpkhdHWlaX\ldoF{\SC{ZYDvdpRmeiCpZX7lJIF{e2G7LDDFR|UxKD1iMD6wNkDPxE1w M4nLVlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF7OE[zNFg{Lz5zOUi2N|A5OzxxYU6=
Freestyle293F Mnu1SpVv[3Srb36gZZN{[Xl? MVuzJIhzew>? NWXFfYVYTGm|cHzhZ4Vu\W62IH;mJHsyPy2jbIDoZU1u\XSqeXytN2heNW2rYn;s[ZJwdmViZoLvcUBpfW2jbjDhcoRzd2enbjDy[YNmeHSxcjDlfJBz\XO|ZXSgbY4hUEWNMkmzJIRmemm4ZXSgSpJm\VO2eXzlNlk{TiClZXzsd{Bi\nSncjCzJIhzeyxiSVO1NEA:KDBwMECyNUDPxE1w MWS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjB7NEK3PUc,OjJyOUSyO|k9N2F-
Freestyle293F MnjBSpVv[3Srb36gZZN{[Xl? MX[zJIhzew>? NHS1V5ZFcXOybHHj[Y1mdnRib3[gX|E4NWGucHjhMY1mfGi7bD2zTH0udWmkb3zldo9v\SCocn;tJIh2dWGwIHHu[JJw\2WwIILlZ4VxfG:{IGS4O|dCKG23dHHueEBmgHC{ZYPz[YQhcW5iSFXLNlk{KGSncnn2[YQhTnKnZWP0fYxmOjl|RjDj[YxteyCjZoTldkA{KGi{czygTWM2OCB;IECuNFAzPiEQvF2u NFTNO|Q9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkC5OFI4QSd-MkKwPVQzPzl:L3G+
HeLa M1i3ZWZ2dmO2aX;uJIF{e2G7 MkfKWJJidnOjY4TpeoF1cW:wIH;mJIh2dWGwIHHu[JJw\2WwIILlZ4VxfG:{IITyZY5{\mWldHXkJIlvKGi3bXHuJGhmVGFiY3XscJMh[nlibIXjbYZmemG|ZTDy[ZBwenSncjDn[Y5mKGG|c3H5MEBC[3Srdnn0fUA:KDBwMEC4JO69VS5? NIPqT4U9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{Mki5O|YyOSd-MkK4PVc3OTF:L3G+
HeLa MUfGeY5kfGmxbjDhd5NigQ>? MYHQZZJ1cWGuIHHnc45qe3RiYXP0bZZqfHliYYSgbJVu[W5iYX7kdo9o\W5icnXj[ZB1d3JiZYjwdoV{e2WmIHnuJGhmVGFiY3XscJMh[29vZYjwdoV{e2mwZzDBVmUh[nlibIXjbYZmemG|ZTDy[ZBwenSncjDn[Y5mKGKjc3XkJJRz[W6|YXP0bZZifGmxbjDhd5NigSxiQXP0bZZqfHliPTCwMlAxQCEQvF2u MVe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjl3N{m0O{c,OjJ7NUe5OFc9N2F-
Freestyle293F NGDzeJZHfW6ldHnvckBie3OjeR?= MX\Jcohq[mm2aX;uJI9nKHerbHSgeJlx\SCDbnTyc4dmdiC{ZXPldJRweiBqdX7rco94diCxcnnnbY4qKGW6cILld5Nm\CCrbjDGdoVme3S7bHWyPVNHKGOnbHzzMEBKSzVyIE2gNE4xODJzIN88UU4> NXHUTXBlRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkOxPVk1PzdpPkKzNVk6PDd5PD;hQi=>
Freestyle293F MUjGeY5kfGmxbjDhd5NigQ>? MnTtTY5pcWKrdHnvckBw\iCDbnTyc4dmdiC{ZXPldJRweiCWOEe3RUBufXSjboSgLJVvc26xd36gc5Jq\2mwKTDlfJBz\XO|ZXSgbY4hTnKnZYP0fYxmOjl|RjDj[YxteyxiSVO1NEA:KDBwMECyOkDPxE1w M{TyWFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ|MUm5OFc4Lz5{M{G5PVQ4PzxxYU6=
COS7 M3PQOmZ2dmO2aX;uJIF{e2G7 NYfXNWVDOiCqcoO= M{CwTWRqe3CuYXPlcYVvfCCxZjDbN2heKF13YXzwbIEuTEiWIH\yc40hdW:3c3WgZY5lem:pZX6gdoVk\XC2b4Kg[ZhxemW|c3XkJIlvKG2xbnvlfUBEV1N5IHPlcIx{KGGodHXyJFIhcHK|IHL5JJNkcW62aXzsZZRqd25iY3;1cpRqdmdiYX7hcJl{cXNuIFnDOVAhRSByLkCwNUDPxE1w MlfnQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN3Mke4NVYoRjJ|NUK3PFE3RC:jPh?=
C2C12 NUjHSpJKTnWwY4Tpc44h[XO|YYm= MUm1JIRigXN? NUXsOZQ3SWexbnnzeEBi[3Srdnn0fUBifCCjbnTyc4dmdiC{ZXPldJRweiCneIDy[ZN{\WRiaX6gcY92e2ViQ{LDNVIh[2WubIOgZZN{\XO|ZXSgZZMhd3O2ZX;icIF{fCCmaX\m[ZJmdnSrYYTpc44h[W[2ZYKgOUBl[Xm|LDDFR|UxKD1iMD6wNFAxPSEQvF2u NIf4b2w9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEmwNFI6OCd-MkS5NFAzQTB:L3G+
C2C12 NGXHWJZHfW6ldHnvckBie3OjeR?= MXnB[49vcXO2IHHjeIl3cXS7IHH0JIh2dWGwIHHu[JJw\2WwIILlZ4VxfG:{IHX4dJJme3OnZDDpckBud3W|ZTDDNmMyOiClZXzsd{BjgSCjbnTyc4dmdi2|cHXjbYZq[yC{ZYPwc45{\SCnbHXt[Y51NWS{aY\lckBtfWOrZnXyZZNmKHKncH;yeIVzKGenbnWgZZN{[XluIFXDOVAhRSByLkCwNFE{KM7:TT6= NFO3fGo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUGyNVk3PCd-MkWxNlE6PjR:L3G+
COS7 NH35UoZHfW6ldHnvckBie3OjeR?= MkDKNlQhcHK| NHrtWYVC\2:waYP0JIFkfGm4aYT5JIF1KGi3bXHuJGFTKGW6cILld5Nm\CCrbjDB[pJq[2GwIHfy[YVvKG2xbnvlfUBEV1N5IHPlcIx{KGGodHXyJFI1KGi{czDifUBtfWOrZnXyZZNmKHKncH;yeIVzKGenbnWgZZN{[XluIFXDOVAhRSByLkCwN{DPxE1w Mk\IQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh2NUS4OFkoRjJ6NEW0PFQ6RC:jPh?=
Shionogi MY\GeY5kfGmxbjDhd5NigQ>? NHHOV4oyOCCyTR?= NXvufHZKUW6mdXP0bY9vKG:oIIDyc4xq\mW{YYTpc44hd2ZibX;1d4UhW2irb37v[4kh[2WubIOgZZQhOTBicF2= NUjYT5dFRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUe3NVE5PTVpPkG3O|EyQDV3PD;hQi=>
MCF7 MUjGeY5kfGmxbjDhd5NigQ>? MoHYN|AhfU1? MnnSNlQhcHK| NGnrcJFCdnSjZ3;ubZN1KGGldHn2bZR6KGG2IFHSJIlvKGi3bXHuJG1ETjdiY3XscJMh[XO|ZYPz[YQh[XNicnXkeYN1cW:wIHnuJGFTKGyndnXsJIF1KDNyIIXNJIFnfGW{IEK0JIhzeyCkeTDX[ZN1\XKwIHLsc5Qh[W6jbInzbZMhemWuYYTpeoUhfG9iY3;ueJJwdA>? NWDlUJM1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkKwNVQ4PTFpPkKyNFE1PzVzPD;hQi=>

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
Cyclin D1 / Cyclin D2 / Cyclin D3 / Cyclin E2 / Cyclin A1 / AR; 

PubMed: 26372468     


HPr-1AR cells were treated with 10 nM DHT or vehicle control for 24–48 hours (h), and immunoblot analysis of cell lysates reveals that cyclin D1 and D2 protein expression decreased substantially with DHT treatment compared to vehicle.

p-CDK2 / CDK2 / CDK4 / CDK6 / CDKN1A / p-RB / RB ; 

PubMed: 26372468     


HPr-1AR cells were treated with 10 nM DHT or vehicle control for 24–48 hours (h). Immunoblot analysis of cell lysates reveals that CDK4 and CDK6 protein expression decreased and CDKN1A expression increased with DHT treatment compared to vehicle. CDK2 phosphorylation at threonine 160 (T160) decreased nearly 50% with androgen treatment at 24 and 48 hours, albeit not significantly, and total CDK2 protein expression remained unchanged. Relative to total RB expression, the levels of various phosphorylated forms of RB (S780 and S807/811) decreased over time with androgen treatment. 

p27 / p-p27 ; 

PubMed: 22139837     


CWR22Rv1 or CWR22R3 cells were stimulated with 10 nm DHT for 6 h, with the addition of MG132 during the last 2 h before harvesting. Proteins were then immunoblotted.

AR / PP1 ; 

PubMed: 26636645     


HeLa cells were transfected with Flag-PP1α and HA-AR and then incubated for overnight in androgen-depleted medium without or with androgen (10 nM of DHT) as indicated for blotting. 

26372468 22139837 26636645
Immunofluorescence
FOXO1 / p27 ; 

PubMed: 22139837     


CWR22R3 cells cultured in medium with CDS serum were treated without/with DHT (10 nm) for 4 h. The cells were immunostained for FOXO1 and p27 and examined with a confocal microscope. 

AKT(S473) / PKCα(S657) ; 

PubMed: 22139837     


CWR22R3 cells cultured in medium with CDS serum were treated without/with 10 nm DHT (−/+ DHT) for 4 h. The cells were immunostained for AKT or PKCα phosphorylation and examined with a confocal microscope. Bars: 20 μm

22139837
In vivo DHT-treated SOD1-G93A mice demonstrate ameliorated muscle atrophy and increased body weight, which is associated with stronger grip-strength. DHT treatment increases the expression of insulin-like growth factor-1 in muscle, which can exert myotrophic as well as neurotrophic effects through retrograde transport. DHT treatment attenuates neuromuscular junction denervation, and axonal and motoneuron loss. DHT-treated SOD1-G93A mice demonstrates improvement in motor behavior as assessed by rota-rod and gait analyses, and an increased lifespan[2].

Protocol

Cell Research:

[1]

- Collapse
  • Cell lines: Bladder cancer cells
  • Concentrations: 1 nM
  • Incubation Time: 24 h
  • Method:

    Bladder cancer cells at a density of 50-60% confluence in 24-well plates are co-transfected with 250 ng of MMTV-luc reporter plasmid DNA and 2.5 ng of PRL-TK-luc plasmid DNA. After 6 h of transfection, the medium is replaced with another medium supplemented with charcoal-stripped FBS in the presence or absence of ligands (DHT, HF, or both) for 24 h. Cells were harvested, lysed, and assayed for luciferase activity.


    (Only for Reference)
Animal Research:

[2]

- Collapse
  • Animal Models: SOD1-G93A mutant mice with the congenic C57BL/6J background
  • Dosages: 5 mg
  • Administration: silastic implant
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 58 mg/mL (199.69 mM)
Ethanol 58 mg/mL (199.69 mM)
Water Insoluble

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 290.44
Formula

C19H30O2

CAS No. 521-18-6
Storage powder
in solvent
Synonyms androstanolone, stanolone, 5α-DHT
Smiles CC12CCC(=O)CC1CCC3C2CCC4(C3CCC4O)C

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Dosage mg/kg Average weight of animals g Dosing volume per animal ul Number of animals
Step 2: Enter the in vivo formulation ()
% DMSO % % Tween 80 % ddH2O
CalculateReset

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT04032067 Not yet recruiting Drug: GV1001 placebo|Drug: Proscar placebo Benign Prostatic Hyperplasia (BPH) GemVax & Kael August 28 2019 Phase 3

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Androgen Receptor Signaling Pathway Map

Related Androgen Receptor Products

Tags: buy Dihydrotestosterone (DHT) | Dihydrotestosterone (DHT) supplier | purchase Dihydrotestosterone (DHT) | Dihydrotestosterone (DHT) cost | Dihydrotestosterone (DHT) manufacturer | order Dihydrotestosterone (DHT) | Dihydrotestosterone (DHT) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID